ArticleOncoimmunology2013
Fusions between dendritic cells and whole tumor cells as anticancer vaccines.
Article in Oncoimmunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Oxygen-carrying nanovaccine potentiates cancer immunotherapy for heterogeneous solid tumors.Materials today. Bio · 2026Article
- Fabrication and functional validation of a hybrid biomimetic nanovaccine (HBNV) againstBioactive materials · 2025Article
- Development of Cell Technologies Based on Dendritic Cells for Immunotherapy of Oncological Diseases.Biomedicines · 2024Review
- Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinoma.Human vaccines & immunotherapeutics · 2023Review
- Engineered tumor cell-derived vaccines against cancer: The art of combating poison with poison.Bioactive materials · 2023Review
- Cell fusion in cancer hallmarks: Current research status and future indications.Oncology letters · 2021Review
- Insights Into Dendritic Cells in Cancer Immunotherapy: From Bench to Clinical Applications.Frontiers in cell and developmental biology · 2021Review
- Dendritic Cells in Anticancer Vaccination: Rationale for Ex Vivo Loading or In Vivo Targeting.Cancers · 2020Review
- Immune Escape after Hematopoietic Stem Cell Transplantation (HSCT): From Mechanisms to Novel Therapies.Cancers · 2019Review
- Cytomembrane nanovaccines show therapeutic effects by mimicking tumor cells and antigen presenting cells.Nature communications · 2019Article
- Dendritic-Tumor Fusion Cell-Based Cancer Vaccines.International journal of molecular sciences · 2016Review
- Advances in inducing adaptive immunity using cell-based cancer vaccines: Clinical applications in pancreatic cancer.World journal of gastroenterology · 2016Review
- Dendritic cell-based cancer immunotherapy for colorectal cancer.World journal of gastroenterology · 2016Review
- Article
- Novel analysis of maturation of murine bone-marrow-derived dendritic cells induced by Ginkgo Seed Polysaccharides.Human vaccines & immunotherapeutics · 2015Article
- A novel modulation of structural and functional changes of mouse bone marrow derived dendritic cells (BMDCs) by interleukin-2(IL-2).Human vaccines & immunotherapeutics · 2015Article
- Classification of current anticancer immunotherapies.Oncotarget · 2014Review
- Trial watch: Dendritic cell-based anticancer therapy.Oncoimmunology · 2014Review
- Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies.Human vaccines & immunotherapeutics · 2014Review
- Trial watch: Dendritic cell-based interventions for cancer therapy.Oncoimmunology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Various strategies have been developed to deliver tumor-associated antigens (TAAs) to dendritic cells (DCs). Among these, the fusion of DCs and whole cancer cells can process a broad array of TAAs, including hitherto unidentified molecules, and present them in complex with MHC Class I and II molecules and in the context of co-stimulatory signals. DC-cancer cell fusions have been shown to stimulate potent antitumor immune responses in animal models. In early clinical trials, however, the antitumor effects of DC-cancer cell fusions are not as vigorous as in preclinical settings. This mini-review summarizes recent advances in anticancer vaccines based on DC-cancer cell fusions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.